))
PERMIT Project Comes to an End
Manage episode 333162653 series 2981180
コンテンツは eupatientsforum によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、eupatientsforum またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作権で保護された作品をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
In today’s episode, we will discuss the Horizon 2020 ‘Personalised Medicine Trials’ or PERMIT project, which concluded at the end of June 2022. To help us understand more about the project, its aims and impact, and what comes next, we’ve invited Paula Garcia to speak with us today. Paula is Project Manager at ECRIN, the European Clinical Research Infrastructures Network, the organization that coordinated the PERMIT project.
On June 16th and 17th the PERMIT project consortium, personalised medicine experts, and other invested stakeholders met in Milan (and online) at the Istituto di Recherche Farmacologiche Mario Negri to discuss the recommendations that were developed over the 2.5 years of the project. PERMIT aimed to improve personalised medicines research by establishing recommendations based on a series of workshops held with experts in order to establish recommendations on methodology which can be widely accepted.
Personalised Medicine has enormous value for patients, as it can reduce trial-and-error treatments, enable better choices for determining which medications would be most effective, and it can help us also manage rising healthcare costs. By participating in PERMIT, EPF ensured the patient perspective and patient journey were considered throughout the workshops, and ultimately, the recommendations put forward by expert groups.
To learn more about the project, head to: https://permit-eu.org/
PERMIT has received funding from Horizon 2020, under grant agreement number 874825.
63 つのエピソード
シェア
